Literature DB >> 14529012

Intrathecal morphine for chronic benign pain.

Helmut R Gerber1.   

Abstract

In the treatment of chronic benign pain, the administration of an intrathecal opioid produces a potent analgesia without interfering with the motor and sensory functions of the lower extremities. An intrathecal opioid should be considered only when pain control with conventional oral and systemic administration is inadequate or is associated with unmanageable side effects. A trial period and a psychological evaluation are mandatory prior to implantation of a permanent device. About 40% of the patients need surgical revision for various complications. Hormonal changes may influence sexual behaviour. Catheter granulomas can form with high concentrations of morphine. Adjuvant drugs such as bupivacaine, clonidine and ketamine might be necessary to deal with the development of tolerance to morphine. The sophistication of available technology for intrathecal infusion today far exceeds our knowledge of the potential neurological effects of this treatment modality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529012     DOI: 10.1016/s1521-6896(03)00014-4

Source DB:  PubMed          Journal:  Best Pract Res Clin Anaesthesiol        ISSN: 1521-6896


  6 in total

Review 1.  Intrathecal therapy for chronic pain: current trends and future needs.

Authors:  Salim M Hayek; Michael C Hanes
Journal:  Curr Pain Headache Rep       Date:  2014-01

2.  Progressive adult spinal deformity following placement of intrathecal opioid pump: a report of four cases.

Authors:  Jared W Daniel; Geoffrey F Haft
Journal:  Iowa Orthop J       Date:  2014

3.  Systemic naloxone infusion may trigger spasticity in patients with spinal cord injury: case series.

Authors:  Nancy L Brackett; Emad Ibrahim; Andrei Krassioukov; Charles M Lynne
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

4.  Phosphoproteomics and bioinformatics analyses of spinal cord proteins in rats with morphine tolerance.

Authors:  Wen-Jinn Liaw; Cheng-Ming Tsao; Go-Shine Huang; Chin-Chen Wu; Shung-Tai Ho; Jhi-Joung Wang; Yuan-Xiang Tao; Hao-Ai Shui
Journal:  PLoS One       Date:  2014-01-02       Impact factor: 3.240

Review 5.  Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain.

Authors:  Michael Saulino; Philip S Kim; Erik Shaw
Journal:  J Pain Res       Date:  2014-11-10       Impact factor: 3.133

6.  [What became of Prialt®? : Observational study on the use of ziconotide in the treatment of chronic pain].

Authors:  Denise Löschner; Rebecca Dries; Rolf Kalff; Jan Walter; Rupert Reichart
Journal:  Schmerz       Date:  2021-01-28       Impact factor: 1.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.